These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3061349)

  • 21. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
    Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S
    Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simplified ELISA for anti-receptor antibodies in myasthenia gravis.
    Jailkhani BL; Asthana D; Jaffery NF; Kumar R; Ahuja GK
    J Immunol Methods; 1986 Jan; 86(1):115-8. PubMed ID: 3944465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of antibodies to neuronal α7-acetylcholine receptors in myasthenia.
    Lantzova VB; Sepp EK; Kozlovskii AS
    Bull Exp Biol Med; 2011 Jul; 151(3):305-7. PubMed ID: 22451872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of myasthenia gravis with dropped head: a report of 2 cases and review of the literature.
    Tamai M; Hashimoto T; Isobe T; Sato H; Doden T; Nakano T
    Neuromuscul Disord; 2015 May; 25(5):429-31. PubMed ID: 25747003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-MuSK positivity on plasmapheresis liquid in a double seronegative myasthenia gravis patient.
    Renard D; Candon S; Jacob M; Trusson R; Reboul P
    Acta Neurol Belg; 2018 Mar; 118(1):119-120. PubMed ID: 28608313
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993.
    Nakaji S; Oka K; Tanihara M; Takakura K; Takamori M
    Ther Apher; 2000 Apr; 4(2):124-6. PubMed ID: 10805430
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunosorbent treatment in myasthenia gravis.
    Passalacqua S; Splendiani G; Sturniolo A; Costanzi S; Barbera G; Bartoccioni E; Evoli A; Scoppetta C; Adorno D; Di Guilio S
    Prog Clin Biol Res; 1990; 337():285-8. PubMed ID: 2191321
    [No Abstract]   [Full Text] [Related]  

  • 28. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies to synthetic peptide (125-148) of the alpha-subunit of human nicotinic acetylcholine receptor in sera from patients with myasthenia gravis.
    Ohta M; Ohta K; Itoh N; Nishitani H; Hara H; Hayashi K
    Neurology; 1990 Nov; 40(11):1776-8. PubMed ID: 2234435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of disease-specific autoantibodies in seronegative myasthenia gravis.
    Bartoccioni E; Marino M; Evoli A; Ruegg MA; Scuderi F; Provenzano C
    Ann N Y Acad Sci; 2003 Sep; 998():356-8. PubMed ID: 14592896
    [No Abstract]   [Full Text] [Related]  

  • 31. Myasthenia gravis: nicotinic acetylcholine receptors as targets for autoimmune attack.
    Newsom-Davis J; Harcourt G; Beeson D
    Biochem Soc Trans; 1989 Aug; 17(4):635-7. PubMed ID: 2670631
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-acetylcholine receptor antibodies in myasthenia gravis: binding to membrane-bound Torpedo AChR.
    Koethe SM; DuPont BL; Calvo AM; Otterson G; McQuillen MP
    Ann N Y Acad Sci; 1987; 505():557-65. PubMed ID: 3479936
    [No Abstract]   [Full Text] [Related]  

  • 33. Human x human hybridomas from patients with myasthenia gravis: possible tools for idiotypic therapy for myasthenia.
    Blair DA; Mihovilovic M; Agius MA; Fairclough RH; Richman DP
    Ann N Y Acad Sci; 1987; 505():155-67. PubMed ID: 3500665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor.
    Tzartos SJ
    In Vivo; 1988; 2(1):105-10. PubMed ID: 2979808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis.
    Behan PO; Shakir RA; Simpson JA; Burnett AK; Allan TL; Haase G
    Lancet; 1979 Sep; 2(8140):438-40. PubMed ID: 89500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
    Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
    Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current trends in the management of myasthenia gravis: plasmapheresis and immunosuppressive therapy.
    Pollard JD; Basten A; Hassall JE; Kronenberg H; Cobcroft R; Dawkins R
    Aust N Z J Med; 1980 Apr; 10(2):212-7. PubMed ID: 6930213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis.
    Hosokawa S; Oyamaguchi A
    ASAIO Trans; 1990; 36(3):M207-8. PubMed ID: 2252658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
    Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmapheresis in myasthenia gravis.
    Dau PC
    Prog Clin Biol Res; 1982; 88():265-85. PubMed ID: 7100216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.